Oxford researchers funded by the UK blood cancer charity Bloodwise, "have found that high levels of shortened forms of a protein, known as FOXP1, in a patient's lymphoma cells enable the cancer to evade the immune system, potentially nearly halving survival rates for these patients":
There's between a 3 - 15% risk of CLL patients developing DLBLC (Richter's Transformation), with the risk increasing with the time you've lived with CLL, treatment and genetics. A great deal more research needs to be done on how this occurs as well as finding much better ways to treat the condition. Some of our member have DLBLC.
With thanks to CLL/SLL groups.io for posting about the above article.